Perfil metabólico de mulheres não obesas com câncer de mama na pós-menopausa
Carregando...
Data
2023-05-29
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
Objetivo: Avaliar o perfil metabólico de mulheres não obesas com câncer de mama na pós-menopausa comparadas às mulheres não obesas sem câncer de mama. Métodos: Realizou-se estudo clínico de corte transversal. No grupo de estudo foram incluídas 130 mulheres não obesas com diagnóstico histológico de câncer de mama, estádios I a III, idade entre 45-75 anos, em amenorreia ≥ 12 meses e sem doença cardiovascular (DCV) estabelecida. O grupo controle foi constituído de 130 mulheres com os mesmos critérios de inclusão, sem câncer de mama. Os grupos foram pareados por idade e tempo de menopausa e comparados na proporção de 1:1. Foram coletados dados clínicos, antropométricos [índice de massa corpórea (IMC) e circunferência da cintura (CC)] e bioquímicos. Foram consideradas com síndrome metabólica (SM) as mulheres que apresentaram três ou mais critérios diagnósticos: CC > 88 cm; triglicerídeos (TG) 150 mg/dL; HDL colesterol < 50 mg/dL; pressão arterial 130/85 mmHg; glicose 100 mg/dL. Para análise estatística foram empregados o teste t-student, a Distribuição Gama (variáveis assimétricas), o teste do Qui-quadrado e a regressão logística (odds ratio-OR). Resultados: Na comparação entre as características clínicas, observou-se que mulheres com câncer de mama apresentaram maiores médias nos valores de pressão sistólica e diastólica e de glicemia quando comparadas ao controle (p<0.05). Na avaliação dos fatores que influenciam o perfil metabólico foi observada maior ocorrência de SM e de elevação da pressão arterial entre as mulheres tratadas de câncer mama quando comparadas ao controle (30.8% vs 20.0%, e 25.4% vs 14.6%, respectivamente) (p<0.05). E maior porcentagem de mulheres tratadas de câncer de mama apresentava valores acima dos desejáveis de colesterol total e glicemia na comparação com o grupo controle (56.2% vs 43.1% e 29.2% vs 15.4%, respectivamente) (p<0,05). Na análise de risco do perfil metabólico, ajustada para idade e tempo de menopausa, as mulheres com câncer de mama apresentaram risco significativamente maior para SM (OR=2.76, IC 95% 1.48-5.15), e elevação da glicemia OR=2.69, IC 95% 1.46-4.96) e da pressão arterial (OR=3.03, IC 95% 1.51-6.10). Conclusão: Mulheres com câncer de mama não obesas apresentaram maior risco para SM, hipertensão e diabetes, com pior perfil metabólico quando comparadas as mulheres não obesas na pós-menopausa sem câncer de mama.
Objective: To evaluate the metabolic profile of non-obese postmenopausal women with breast cancer compared to non-obese women without breast cancer. Methods: A cross-sectional clinical study was conducted. The study group included 130 non-obese women with histological diagnosis of breast cancer, stages I to III, aged between 45-75 years, with amenorrhea ≥12 months and without established cardiovascular disease (CVD). The control group consisted of 130 women with the same inclusion criteria, but without breast cancer. The groups were matched by age and menopausal status in a 1:1 ratio. Clinical, anthropometric [body mass index (BMI) and waist circumference (WC)], and biochemical data were collected. Women who presented three or more diagnostic criteria were considered to have metabolic syndrome (MS): WC > 88 cm; triglycerides (TG) ≥ 150 mg/dL; HDL cholesterol < 50 mg/dL; blood pressure ≥ 130/85 mmHg; glucose ≥ 100 mg/dL. Statistical analysis employed the t-student test, Gamma Distribution (asymmetric variables), chi-square test, and logistic regression (odds ratio-OR). Results: When comparing clinical characteristics, it was observed that women with breast cancer had higher mean values of systolic and diastolic blood pressure and glucose compared to the control (p<0.05). A higher occurrence of MS and elevated blood pressure was observed among women treated for breast cancer compared to the control (30.8% vs. 20.0% and 25.4% vs. 14.6%, respectively) (p<0.05). A higher percentage of women treated for breast cancer had values above the desirable range for total cholesterol and glucose compared to the control group (56.2% vs. 43.1% and 29.2% vs. 15.4%, respectively) (p<0.05). In the risk analysis of the metabolic profile, adjusted for age and menopausal status, women with breast cancer had a significantly higher risk for MS (OR=2.76, 95% CI 1.48-5.15), elevated glucose (OR=2.69, 95% CI 1.46-4.96), and elevated blood pressure (OR=3.03, 95% CI 1.51-6.10). Conclusion: Non-obese women with breast cancer had a higher risk for MS, hypertension, and diabetes, with a worse metabolic profile compared to non-obese postmenopausal women without breast cancer
Objective: To evaluate the metabolic profile of non-obese postmenopausal women with breast cancer compared to non-obese women without breast cancer. Methods: A cross-sectional clinical study was conducted. The study group included 130 non-obese women with histological diagnosis of breast cancer, stages I to III, aged between 45-75 years, with amenorrhea ≥12 months and without established cardiovascular disease (CVD). The control group consisted of 130 women with the same inclusion criteria, but without breast cancer. The groups were matched by age and menopausal status in a 1:1 ratio. Clinical, anthropometric [body mass index (BMI) and waist circumference (WC)], and biochemical data were collected. Women who presented three or more diagnostic criteria were considered to have metabolic syndrome (MS): WC > 88 cm; triglycerides (TG) ≥ 150 mg/dL; HDL cholesterol < 50 mg/dL; blood pressure ≥ 130/85 mmHg; glucose ≥ 100 mg/dL. Statistical analysis employed the t-student test, Gamma Distribution (asymmetric variables), chi-square test, and logistic regression (odds ratio-OR). Results: When comparing clinical characteristics, it was observed that women with breast cancer had higher mean values of systolic and diastolic blood pressure and glucose compared to the control (p<0.05). A higher occurrence of MS and elevated blood pressure was observed among women treated for breast cancer compared to the control (30.8% vs. 20.0% and 25.4% vs. 14.6%, respectively) (p<0.05). A higher percentage of women treated for breast cancer had values above the desirable range for total cholesterol and glucose compared to the control group (56.2% vs. 43.1% and 29.2% vs. 15.4%, respectively) (p<0.05). In the risk analysis of the metabolic profile, adjusted for age and menopausal status, women with breast cancer had a significantly higher risk for MS (OR=2.76, 95% CI 1.48-5.15), elevated glucose (OR=2.69, 95% CI 1.46-4.96), and elevated blood pressure (OR=3.03, 95% CI 1.51-6.10). Conclusion: Non-obese women with breast cancer had a higher risk for MS, hypertension, and diabetes, with a worse metabolic profile compared to non-obese postmenopausal women without breast cancer
Descrição
Palavras-chave
Câncer de mama, Síndrome metabólica, Disfunção metabólica, Obesidade, Menopausa, Breast cancer, Metabolic Dysfunction, Metabolic Syndrome, Obesity, Menopause